Elevance Health Inc

Elevance Health Inc (ELV) Stock Analysis

$428.090

+2.825 (+0.66%)At close

Loading chart…
High
434.000
Open
428.820
VWAP
427.96
Volume
2.12M
Mkt Cap
124.52B
Low
421.780
Amount
905.64M
EV/EBITDA, TTM
10.62

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

AI analysis of Elevance Health Inc (ELV)

Buy

Elevance Health Inc is a good buy right now due to its current price of $412.7 being below the analyst price target of $480 from BofA, indicating a potential upside of 16.3%. Additionally, the stock's RSI of 71.921 suggests it is nearing overbought territory, but the strong earnings performance with a 20.55% EPS surprise last quarter supports continued growth. The main risk is the hedge fund selling trend, which has increased by 135.25% over the last quarter, indicating potential bearish sentiment among institutional investors.

Valuation Metrics

The current forward P/E ratio for Elevance Health Inc (ELV) is 13.68, compared to its 5-year average forward P/E of 13.76.

Forward P/E

Fair
5Y Average P/E
13.76
Current P/E
13.68
Overvalued
15.58
Undervalued
11.94

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.29
Current EV/EBITDA
10.62
Overvalued
11.86
Undervalued
8.73

Forward P/S

Fair
5Y Average P/S
0.58
Current P/S
0.46
Overvalued
0.72
Undervalued
0.44

Alphio AI Price Scenarios for ELV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ELV

$456.04

Scenario price

B

Base

Base · 50%ELV

$450.58

Scenario price

B

Bear

Bear · 25%ELV

$379.11

Scenario price

Whales holding ELV

A

ARGA Investment Management, LLC

+ HoldingELV

+12.89%

3M Return

G

Grantham Mayo Van Otterloo & Co. LLC

+ HoldingELV

+7.80%

3M Return

S

Sanders Capital, LLC

+ HoldingELV

+7.60%

3M Return

T

Trajan Wealth, L.L.C.

+ HoldingELV

+6.51%

3M Return

Y

Yacktman Asset Management LP

+ HoldingELV

+5.83%

3M Return

M

Manulife Asset Management

+ HoldingELV

+5.55%

3M Return

ELV FAQ — answered by Alphio AI

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Elevance Health Inc is a good buy right now due to its current price of $412.7 being below the analyst price target of $480 from BofA, indicating a potential upside of 16.3%. Additionally, the stock's RSI of 71.921 suggests it is nearing overbought territory, but the strong earnings performance with a 20.55% EPS surprise last quarter supports continued growth. The main risk is the hedge fund selling trend, which has increased by 135.25% over the last quarter, indicating potential bearish sentiment among institutional investors.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading